Abacavir / dolutegravir / lamivudine

Screen patients for HLA-B*5701 allele before starting treatment to identify those at higher risk of anaphylaxis.

Monitor renal function regularly and adjust the dosage in patients with pre-existing renal impairment.

Use extreme caution in patients with hepatitis B/C virus and HIV co-infection. Prior to starting the medication, screen patients for hepatitis B/C and HIV coinfection. If hepatitis exacerbation occurs, discontinue the medication and provide appropriate medical management for hepatitis exacerbation.

Use caution with pre-existing peripheral neuropathy. Before starting the medication, conduct a comprehensive evaluation of the patient's neurological status. Discontinue the offending medication and provide symptomatic treatment such as pain relief, physical therapy, and neuroprotective agents under the guidance of a neurologist or specialist in HIV care.

Use extreme caution with a history of hepatic disease or known risk factors for liver disease (e.g., alcoholism). Monitor liver function regularly during treatment. If hepatotoxicity occurs, discontinue the medication and provide appropriate medical management and supportive care.

Use caution treated with combination antiretroviral therapy. Gradual initiation of therapy, close monitoring during initial treatment, and screening for potential infections before starting the medication. Management may involve symptomatic treatment, temporary discontinuation of the drugs, and the use of anti-inflammatory medications under the supervision of a healthcare professional.

Use extreme caution with underlying cardiac disease or risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, and smoking). Monitor cardiovascular health in patients with pre-existing risk factors. If myocardial infarction occurs, seek immediate medical attention and provide appropriate treatment.

Use extreme caution with a history of depression or other psychiatric illness. Perform a thorough psychiatric assessment, including screening for depression and suicidal ideation. Monitor the patient regularly for mood changes and provide psychosocial support. Consider a temporary interruption or discontinuation of the medication under close medical supervision. Offer counseling, therapy, or pharmacological interventions to address the patient's mental health concerns.